StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Implanon / Nexplanon by Year

Implanon / Nexplanon (etonogestrel implant, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

Merck Implanon / Nexplanon: $680M in FY2020, down 13.6% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
680
Period ended Dec 31, 2020
Change on a year earlier
-13.6%
787 in FY2019
History
5 years
Since FY2016
Sources
3
Documents cited below

Where the FY2020 figure comes from

Source: Form 10-K (filed 2021-02-25) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedImplanon / Nexplanon (etonogestrel implant, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
FY2020Dec 31, 2020680-13.6%Form 10-K (filed 2021-02-25) ↗
FY2019Dec 31, 2019787+11.9%Form 10-K (filed 2021-02-25) ↗
FY2018Dec 31, 2018703+2.5%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 2017686+13.2%Form 10-K (filed 2020-02-26) ↗
FY2016Dec 31, 2016606–Form 10-K (filed 2019-02-27) ↗

Breakdown

What makes up implanon / Nexplanon

Cite this data

StockData. (2026). Merck Implanon / Nexplanon ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-nexplanon

See every metric in the Merck KPI table. Data updated Oct 26, 2026.